Harbour Investments Inc. lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 36.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,308 shares of the medical research company’s stock after selling 2,987 shares during the period. Harbour Investments Inc.’s holdings in Amgen were worth $2,237,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently bought and sold shares of AMGN. Quest 10 Wealth Builders Inc. boosted its stake in Amgen by 220.0% during the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after buying an additional 55 shares during the last quarter. Wellington Altus USA Inc. increased its stake in Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after acquiring an additional 34 shares during the last quarter. Nvwm LLC raised its holdings in shares of Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after acquiring an additional 66 shares in the last quarter. PFS Partners LLC boosted its position in shares of Amgen by 95.5% during the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 42 shares during the last quarter. Finally, TOWER TRUST & INVESTMENT Co bought a new position in shares of Amgen during the 3rd quarter valued at approximately $38,000. 76.50% of the stock is currently owned by institutional investors.
Amgen Stock Down 3.1%
NASDAQ AMGN opened at $443.89 on Thursday. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60. Amgen Inc. has a 52 week low of $312.39 and a 52 week high of $483.99. The firm has a market capitalization of $240.10 billion, a price-to-earnings ratio of 25.75, a PEG ratio of 3.19 and a beta of 0.43. The company has a fifty day moving average of $428.15 and a two-hundred day moving average of $382.85.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating the consensus estimate of $5.79 by $0.66. The business had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.64 earnings per share. On average, analysts predict that Amgen Inc. will post 23.37 earnings per share for the current year.
Amgen Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is 58.47%.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on AMGN. Oppenheimer restated an “outperform” rating on shares of Amgen in a research report on Friday, October 23rd. Canaccord Genuity Group lifted their price objective on shares of Amgen from $384.00 to $440.00 and gave the stock a “hold” rating in a research note on Wednesday, November 4th. The Goldman Sachs Group lifted their price objective on shares of Amgen from $481.00 to $536.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Scotiabank upped their target price on shares of Amgen from $500.00 to $530.00 and gave the company a “sector outperform” rating in a research report on Wednesday, November 4th. Finally, Cantor Fitzgerald increased their price target on shares of Amgen from $440.00 to $465.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $425.69.
Get Our Latest Report on Amgen
Amgen Company Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Featured Articles
- Five stocks we like better than Amgen
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
